Cultured Epidermal Homograft Developed by Domestic Company

Published: 2005-03-22 06:58:00

Updated: 2005-03-22 06:58:00

The Korea Food and Drug Administration (KFDA) said it has approved market authorization of Tego Science's Kaloderm, a cultured epidermal homograft (CEH) for skin replacement and wound healing, effective March 21st.

According to the company, Kaloderm carries out the protective functions of the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK